The comprehensive report provides an analysis of Rhopressa (netarsudil ophthalmic solution) market potential and market share analysis in the Glaucoma therapeutics space across the 7MM from 2019 to 2032. The report also helps you to understand the Rhopressa (netarsudil ophthalmic solution) clinical and commercial developments along with parameters like the drug’s Mechanism of Action (MOA), Route of Administration (ROA), dosage, and special designations.
Rhopressa (netarsudil ophthalmic solution) Drug Insight
RHOPRESSA (Netarsudil ophthalmic solution 0.02%) serves as a valuable intervention for individuals grappling with elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension. The active component, Netarsudil, functions as a Rho kinase inhibitor, showcasing its therapeutic efficacy in reducing IOP. Its chemical nomenclature is (S)-4-(3-amino-1-(isoquinolin-6-yl-amino)-1-oxopropan-2-yl) benzyl 2,4-dimethylbenzoate dimesylate.
In the United States, this solution is recognized by the name RHOPRESSA, while in the European Union, it goes by the name Rhokiinsa. This sterile, isotonic, buffered aqueous solution of netarsudil dimesylate is specifically formulated for topical application to the eye, featuring a pH of approximately 5 and an osmolality of approximately 295 mOsmol/kg.
Each milliliter of RHOPRESSA contains 0.2 mg of netarsudil, equivalent to 0.28 mg of netarsudil dimesylate. A preservative, benzalkonium chloride at 0.015%, is included in the formulation. The inactive ingredients such as boric acid, mannitol, and sodium hydroxide serve the purpose of adjusting pH, along with water for injection.
It’s noteworthy that RHOPRESSA has successfully completed Phase III clinical trials in Japan, reflecting a significant milestone in its development and reinforcing its potential as a therapeutic option for managing intraocular pressure. As advancements in ocular health continue, RHOPRESSA stands at the forefront, offering hope and tangible solutions for those navigating the complexities of glaucoma and ocular hypertension.
Rhopressa (netarsudil ophthalmic solution) – Commercial Development Activities
In November 2022, Alcon announced the successful completion of its acquisition of Aerie Pharmaceuticals Inc. This strategic move is poised to strengthen Alcon’s position in the ophthalmic pharmaceutical sector, augmenting its portfolio of commercial products and development pipeline.
Through the transaction, Alcon has added the commercial products Rocklatan(netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa(netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease. Alcon has also acquired a pipeline of ophthalmic pharmaceutical product candidates, with the opportunity to leverage Aerie’s existing research and development capabilities.
Stay ahead of the competition by leveraging key insights and evolving trends in the market @
Key Highlights of the Rhopressa (netarsudil ophthalmic solution) Market Report
- The report contains the forecasted sales evaluation of Rhopressa (netarsudil ophthalmic solution) for Glaucoma till 2032.
- It provides comprehensive coverage of late-stage emerging therapies for Glaucoma treatment.
- The report also features qualitative and quantitative analysis with analysts and KOL views for Rhopressa (netarsudil ophthalmic solution) in Glaucoma.
Why Rhopressa (netarsudil ophthalmic solution) Market Report?
- The anticipated market data for Rhopressa (netarsudil ophthalmic solution) in the context of Glaucoma will provide valuable support in decision-making processes concerning therapeutic portfolios. This forecast will serve to identify and understand the overall scenario of Rhopressa, enables to make informed decisions about its role and potential impact within their therapeutic portfolios.
- A comprehensive market forecast for Rhopressa (netarsudil ophthalmic solution) will play a vital role in elucidating how the drug competes with other emerging therapies within the dynamic therapeutics landscape. This analysis will provide insights into the positioning of Rhopressa, its competitive edge, and its overall impact on the evolving landscape of therapeutic options.
- Conducting a comprehensive market forecast for Rhopressa (netarsudil ophthalmic solution) will facilitate an in-depth analysis of its clinical trial progress. This examination will encompass a detailed assessment of the drug’s clinical, regulatory, and commercial aspects, providing valuable insights into its advancements.
- The report additionally offers future market assessments for the Rhopressa (netarsudil ophthalmic solution) market in the context of Glaucoma across the 7 Major Markets. It includes advanced qualitative analyses such as a SWOT analysis, insights from expert analysts, a comprehensive overview of market competitors, and a brief analysis of other emerging therapies within the Glaucoma landscape. This multifaceted approach ensures a thorough understanding of the Rhopressa market, incorporating both quantitative and qualitative perspectives, aiding in making well-informed decisions in the dynamic field of glaucoma therapeutics.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
Related Reports By DelveInsight:
DelveInsight’s, “Glaucoma Pipeline Insight” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Some of the key companies in the Glaucoma TTakeda, Argenx, Keros Therapeutics, Principia Biopharma, Momenta Pharmaceuticals, Veralox Therapeutics, Novartis Pharmaceuticals, Pfizer, HUTCHMED, Genosco, UCB, and others.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Explore success with our case study on R&D, Manufacturing & Commercial Capabilities. Uncover insights for strategic growth in the industry @ https://www.delveinsight.com/case-study/r-and-d-landscape-assessment
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices